--- title: "Integra LifeSciences Earnings Call: Mixed Sentiment and Strategic Advancements" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/263817350.md" description: "Integra LifeSciences' recent earnings call revealed mixed sentiment, showcasing operational successes alongside challenges. The company reported a 5% organic revenue growth, with total revenues of $402 million and an adjusted EPS of $0.54, exceeding guidance. However, supply chain disruptions and challenges in the ENT and Private Label segments led to a lowered full-year guidance of $1.62 billion to $1.64 billion. Despite a gross margin decline to 62.9%, the company anticipates modest growth in 2026, driven by strategic initiatives and cost-saving measures." datetime: "2025-11-01T00:05:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/263817350.md) - [en](https://longbridge.com/en/news/263817350.md) - [zh-HK](https://longbridge.com/zh-HK/news/263817350.md) --- > 支持的语言: [English](https://longbridge.com/en/news/263817350.md) | [繁體中文](https://longbridge.com/zh-HK/news/263817350.md) # Integra LifeSciences Earnings Call: Mixed Sentiment and Strategic Advancements The recent earnings call for Integra LifeSciences presented a mixed sentiment, reflecting both operational successes and ongoing challenges. The company showcased strong operational efficiency and strategic advancements, such as the early relaunch of key products. However, these positives were tempered by supply chain disruptions, challenges in the ENT and Private Label segments, and a lowered full-year guidance, indicating a mixed performance overall. ## Strong Organic Revenue Growth Despite facing several challenges, Integra LifeSciences achieved an impressive organic revenue growth of approximately 5% year-over-year. The total revenues for the quarter reached $402 million, highlighting the company’s ability to sustain growth even in a challenging environment. ## Adjusted EPS Exceeds Guidance The company’s adjusted EPS for the quarter was $0.54, surpassing the top end of the guidance range. This achievement reflects strong operational efficiency and effective cost management, showcasing the company’s ability to optimize its operations. ## Significant Improvement in Integra Skin Production Integra LifeSciences reported a significant improvement in its Integra Skin manufacturing yields, which increased by more than 50%. Additionally, inventory levels have increased by 2.5 times since January, indicating a robust production and inventory management strategy. ## Successful Relaunch of PriMatrix and Durepair The early relaunch of PriMatrix and Durepair, facilitated by a dual sourcing strategy, has improved the company’s supply chain resilience. This strategic move allowed the company to reintroduce these key products ahead of schedule. ## Strong International Growth International revenue for Integra LifeSciences grew by 14.6%, driven by strong demand and renewed product availability. Notably, China showed a remarkable 24% year-over-year increase, underscoring the company’s expanding global footprint. ## Revenue Below Expectations Despite the overall growth, revenue fell below expectations due to two supply interruptions in the CSS business and insufficient safety stock levels. This shortfall highlights the ongoing challenges in maintaining supply chain stability. ## Challenges in ENT and Private Label Business The ENT business remained flat, affected by reimbursement pressures and the timing of capital equipment purchases. Additionally, Private Label sales saw a decline of 12.6%, reflecting challenges in these segments. ## MediHoney Under Pressure Sales of MediHoney were impacted due to ongoing remediation efforts under the Compliance Master Plan, indicating the challenges faced in this product line. ## Lowered Full Year Guidance Integra LifeSciences revised its full-year 2025 revenue and adjusted EPS guidance to $1.62 billion to $1.64 billion and $2.19 to $2.24, respectively. This adjustment reflects the mixed performance and ongoing challenges faced by the company. ## Gross Margin Decline The gross margin for the quarter was reported at 62.9%, a decline of 10 basis points year-over-year. This decrease was attributed to increased remediation costs and tariffs, impacting the company’s profitability. ## Forward-Looking Guidance Looking ahead, Integra LifeSciences has provided updated guidance for the fiscal year 2025, with projected revenue between $1.62 billion and $1.64 billion, and an adjusted EPS range of $2.19 to $2.24. The company remains focused on executing its Compliance Master Plan, improving operational efficiency, and maintaining disciplined cost management. They anticipate modest revenue growth in 2026, supported by strategic initiatives and cost-saving measures expected to yield $25 million to $30 million in savings. In summary, the earnings call for Integra LifeSciences reflected a mixed sentiment, balancing strong operational efficiencies and strategic advancements with ongoing challenges in supply chain and specific business segments. Despite these hurdles, the company remains optimistic about its future growth, supported by strategic initiatives and cost-saving measures. ### 相关股票 - [Integra LifeSciences (IART.US)](https://longbridge.com/zh-CN/quote/IART.US.md) ## 相关资讯与研究 - [Energy Transfer stock is up big in 2026. Is there still time to get in?](https://longbridge.com/zh-CN/news/281629741.md) - [Here's What to Expect From West Pharmaceutical's Next Earnings Report](https://longbridge.com/zh-CN/news/281171474.md) - [Individual investors could get a rare shot at buying into SpaceX from day one](https://longbridge.com/zh-CN/news/281225223.md) - [Raymond James Financial Earnings Preview: What to Expect](https://longbridge.com/zh-CN/news/281024632.md) - [02:03 ETNKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit](https://longbridge.com/zh-CN/news/281131764.md)